Carvedilol
Brand names: Carvedilol, Coreg
At a glance
- Medicare prescriptions, 2024
- 14,723,359
- Medicare drug cost
- $127.1M
- Average cost per prescription
- $8.63
- Clinicians who prescribed it
- 226,899
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
1. INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure left ventricular dysfunction following myocardial infarction in clinically stable patients hypertension
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 22.9%
- Internal Medicine 21.4%
- Cardiology 17.0%
- Nurse Practitioners 16.6%
- Interventional Cardiology 6.5%
- Physician Assistants 4.9%
- Nephrology (Kidney) 3.2%
- General Practice 1.4%
- Geriatric Medicine 1.4%
- Cardiac Electrophysiology 1.2%
- Hospitalist 0.8%
- Heart Failure & Transplant Cardiology 0.7%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 5% from 2019 to 2024.
Biggest change by state since 2019
- New Hampshire +29%
- Maine +26%
- District of Columbia +25%
- Minnesota +24%
- Massachusetts +24%
- Mississippi (smallest change) −7%
- Nebraska (smallest change) −6%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aphena Pharma Solutions - Tennessee, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 6.25 mg | white oval tablet, 8 mm | UPARROWHEAD 56 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | white oval tablet, 13 mm | E 04 |
Waylis Therapeutics LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 3.125 mg | white oval tablet, 6 mm | 39 WP |
| 6.25 mg | white oval tablet, 9 mm | WP 4140 |
| 12.5 mg | white oval tablet, 11 mm | WP 4141 |
| 25 mg | white oval tablet, 14 mm | WP 4142 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
8 recalls since 2020
- Aug 2025 · The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · Class II
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm - Aug 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level. - Aug 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm - Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations - Feb 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit - Jan 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit. - Nov 2021 · Aurobindo Pharma USA Inc. · Class III
Failed Impurities/Degradation Specifications - Aug 2021 · Zydus Pharmaceuticals (USA) Inc · Class II
Presence of Foreign Tablets/Capsules; report of two Paroxetine tablets were found in the bottle
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.